Received Feb 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Suspected Vaccination failure; shingles; postherpetic neuralgia; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. In FEB-2026, more than 2 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Suspected Vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: shingles) and post herpetic neuralgia (Verbatim: postherpetic neuralgia). The outcome of the vaccination failure, shingles and post herpetic neuralgia were not reported. It was unknown if the reporter considered the vaccination failure, shingles and post herpetic neuralgia to be related to Shingrix and Shingrix. It was unknown if the company considered the vaccination failure, shingles and post herpetic neuralgia to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 15-FEB-2026 This case was reported by a patient via interactive digital media. Patient had the Shingrix booster six years ago but still developed shingles a week ago, though it was milder. The rash was uncomfortable, but the nerve pain in my right arm, neck, shoulder, chest, and hand was worse. The batch number was not provided and unable to contact the reporter. This case was considered as suspected vaccination failure as details regarding and laboratory test confirming shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure, more than 2 years after receiving Shingrix (dose 1) and Shingrix (dose 2), in an adult female patient. Based on the available information, a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.